{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:11:14Z","timestamp":1790313074473,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00432-023-04736-9","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T05:02:40Z","timestamp":1680930160000},"page":"7793-7803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity"],"prefix":"10.1007","volume":"149","author":[{"given":"Malek","family":"Shatila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Naz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"S. Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"N. De Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga-Paula","family":"T\u00f6r\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib Ben","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,8]]},"reference":[{"issue":"1","key":"4736_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/JIPO.JIPO_12_18","volume":"1","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Tang T, Ali FS, Johnson DH, Qiao W, Diab A, Wang Y (2018a) The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients\u2019 outcomes. J Immunother Precis Oncol 1(1):7\u201318. https:\/\/doi.org\/10.4103\/JIPO.JIPO_12_18","journal-title":"J Immunother Precis Oncol"},{"key":"4736_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","volume":"68","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Qiao W et al (2019b) Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother 68:553\u2013561. https:\/\/doi.org\/10.1007\/s00262-019-02303-1","journal-title":"Cancer Immunol Immunother"},{"key":"4736_CR3","doi-asserted-by":"publisher","unstructured":"Abu-Sbeih H, Ali FS, Alsaadi D et al (2018b) Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 6:142. https:\/\/doi.org\/10.1186\/s40425-018-0461-4","DOI":"10.1186\/s40425-018-0461-4"},{"key":"4736_CR4","doi-asserted-by":"publisher","unstructured":"Abu-Sbeih H, Ali FS, Wang Y et al. (2019a) Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunotherapy Cancer 7:93. https:\/\/doi.org\/10.1186\/s40425-019-0577-1","DOI":"10.1186\/s40425-019-0577-1"},{"issue":"28","key":"4736_CR5","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36(28):2872\u20132878. https:\/\/doi.org\/10.1200\/JCO.2018.79.0006","journal-title":"J Clin Oncol"},{"key":"4736_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x","journal-title":"Nat Med"},{"key":"4736_CR7","doi-asserted-by":"publisher","unstructured":"Chew V, Toh HC, Abastado JP (2017) Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol 2012:608406. https:\/\/doi.org\/10.1155\/2012\/608406","DOI":"10.1155\/2012\/608406"},{"key":"4736_CR8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/gutjnl-2017-314281","volume":"67","author":"OO Coker","year":"2018","unstructured":"Coker OO, Dai Z, Nie Y et al (2018) (2018) Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 67:1024\u20131032","journal-title":"Gut"},{"issue":"3","key":"4736_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/apt.14173","volume":"46","author":"SP Costello","year":"2017","unstructured":"Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM (2017) Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther 46(3):213\u2013224. https:\/\/doi.org\/10.1111\/apt.14173","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"4736_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335(1):2\u201313. https:\/\/doi.org\/10.1016\/j.mce.2010.04.005","journal-title":"Mol Cell Endocrinol"},{"key":"4736_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07472-1","author":"RS Dalal","year":"2022","unstructured":"Dalal RS, McClure EL, Marcus J et al (2022) Comparative long-term drug survival of vedolizumab, adalimumab, and infliximab in biologic-na\u00efve patients with ulcerative colitis. Dig Dis Sci. https:\/\/doi.org\/10.1007\/s10620-022-07472-1","journal-title":"Dig Dis Sci"},{"key":"4736_CR12","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.1038\/s41467-021-27349-7","volume":"12","author":"Y Deng","year":"2021","unstructured":"Deng Y, Xia X, Zhao Y et al (2021) Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun 12:7041. https:\/\/doi.org\/10.1038\/s41467-021-27349-7","journal-title":"Nat Commun"},{"issue":"4","key":"4736_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","volume":"6","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Kicinski M, Blank CU et al (2020) Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive Pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 6(4):519\u2013527. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5570","journal-title":"JAMA Oncol"},{"issue":"6","key":"4736_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.17235\/reed.2022.8618\/2022","volume":"114","author":"FM Fern\u00e1ndez-Gord\u00f3n S\u00e1nchez","year":"2022","unstructured":"Fern\u00e1ndez-Gord\u00f3n S\u00e1nchez FM, G\u00f3mez-Dom\u00ednguez E, Paredes Ruiz D et al (2022) Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury. Rev Esp Enferm Dig 114(6):356\u2013357. https:\/\/doi.org\/10.17235\/reed.2022.8618\/2022","journal-title":"Rev Esp Enferm Dig"},{"key":"4736_CR15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and Unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res off J Am Assoc Cancer Res 22:886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res"},{"key":"4736_CR16","doi-asserted-by":"publisher","unstructured":"Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S (2017) Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. In: Kalinski P. (eds) Tumor immune microenvironment in cancer progression and cancer therapy. Advances in experimental medicine and biology, vol 1036. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-319-67577-0_2","DOI":"10.1007\/978-3-319-67577-0_2"},{"key":"4736_CR17","doi-asserted-by":"publisher","unstructured":"Gaucher L, Adda L, S\u00e9journ\u00e9 A et al (2021) Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation. Therapeut Adv Med Oncol. https:\/\/doi.org\/10.1177\/1758835921996656","DOI":"10.1177\/1758835921996656"},{"key":"4736_CR18","doi-asserted-by":"publisher","unstructured":"Giles AJ, Hutchinson MKND, Sonnemann HM et al (2018) Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer 6:51. https:\/\/doi.org\/10.1186\/s40425-018-0371-5","DOI":"10.1186\/s40425-018-0371-5"},{"issue":"8","key":"4736_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/OP.20.00002","volume":"16","author":"Z Gong","year":"2020","unstructured":"Gong Z, Wang Y (2020) Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. JCO Oncol Pract 16(8):453\u2013461","journal-title":"JCO Oncol Pract"},{"issue":"6371","key":"4736_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"key":"4736_CR21","doi-asserted-by":"publisher","unstructured":"Granier C, De Guillebon E, Blanc C, et al (2017) Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open 2(2):e000213. https:\/\/doi.org\/10.1136\/esmoopen-2017-000213","DOI":"10.1136\/esmoopen-2017-000213"},{"issue":"28","key":"4736_CR22","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 33(28):3193\u20133198. https:\/\/doi.org\/10.1200\/JCO.2015.60.8448","journal-title":"J Clin Oncol"},{"issue":"7","key":"4736_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/01.meg.0000108345.41221.c2","volume":"16","author":"I Kirman","year":"2004","unstructured":"Kirman I, Whelan RL, Nielsen OH (2004) Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease. Eur J Gastroenterol Hepatol 16(7):639\u2013641. https:\/\/doi.org\/10.1097\/01.meg.0000108345.41221.c2","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"4736_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/CJI.0000000000000268","volume":"42","author":"C Lesage","year":"2019","unstructured":"Lesage C, Longvert C, Prey S et al (2019) Incidence and clinical impact of anti-TNF\u03b1 treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the mecolit survey. J Immunother 42(5):175\u2013179. https:\/\/doi.org\/10.1097\/CJI.0000000000000268","journal-title":"J Immunother"},{"key":"4736_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L et al (2013) A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. All Asth Clin Immun 9:30. https:\/\/doi.org\/10.1186\/1710-1492-9-30","journal-title":"All Asth Clin Immun"},{"key":"4736_CR26","doi-asserted-by":"publisher","unstructured":"Lukin D, Faleck D, Xu R et al (2022) Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis. Clin Gastroenterol Hepatol 20(1):126\u2013135. https:\/\/doi.org\/10.1016\/j.cgh.2020.10.003","DOI":"10.1016\/j.cgh.2020.10.003"},{"key":"4736_CR27","doi-asserted-by":"publisher","unstructured":"Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM (2021) Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases. Front Cell Dev Biol. 9:612830. https:\/\/doi.org\/10.3389\/fcell.2021.612830","DOI":"10.3389\/fcell.2021.612830"},{"issue":"52","key":"4736_CR28","doi-asserted-by":"publisher","first-page":"19896","DOI":"10.1074\/jbc.RA119.010379","volume":"294","author":"N Maeda","year":"2019","unstructured":"Maeda N, Maruhashi T, Sugiura D, Shimizu K, Okazaki IM, Okazaki T (2019) Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells. J Biol Chem 294(52):19896\u201319906. https:\/\/doi.org\/10.1074\/jbc.RA119.010379","journal-title":"J Biol Chem"},{"key":"4736_CR29","doi-asserted-by":"publisher","unstructured":"Maleki Vareki S (2018) High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunotherapy Cancer 6:157. https:\/\/doi.org\/10.1186\/s40425-018-0479-7","DOI":"10.1186\/s40425-018-0479-7"},{"key":"4736_CR30","doi-asserted-by":"publisher","unstructured":"Maslov DV, Tawagi K, Kc M et al. (2021) Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J Immunother Cancer 9(7):e002261. https:\/\/doi.org\/10.1136\/jitc-2020-002261","DOI":"10.1136\/jitc-2020-002261"},{"key":"4736_CR31","doi-asserted-by":"publisher","unstructured":"McGranahan N, Swanton C (2017) Cancer evolution constrained by the immune microenvironment. Cell 170(5):825\u2013827. https:\/\/doi.org\/10.1016\/j.cell.2017.08.012","DOI":"10.1016\/j.cell.2017.08.012"},{"key":"4736_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"issue":"1","key":"4736_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","volume":"149","author":"P Moayyedi","year":"2015","unstructured":"Moayyedi P, Surette MG, Kim PT et al (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149(1):102-109.e6. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.001","journal-title":"Gastroenterology"},{"issue":"4","key":"4736_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","volume":"27","author":"A Montfort","year":"2021","unstructured":"Montfort A, Filleron T, Virazels M et al (2021) Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase ib clinical trial. Clin Cancer Res 27(4):1037\u20131047. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3449","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4736_CR35","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.eururo.2014.06.042","volume":"67","author":"B Montgomery","year":"2015","unstructured":"Montgomery B, Kheoh T, Molina A et al (2015) Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol 67(5):866\u2013873. https:\/\/doi.org\/10.1016\/j.eururo.2014.06.042","journal-title":"Eur Urol"},{"key":"4736_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11864-014-0320-6","volume":"16","author":"C Ndibe","year":"2015","unstructured":"Ndibe C, Wang CG, Sonpavde G (2015) Corticosteroids in the management of prostate cancer: a critical review. Curr Treat Options in Oncol 16:6. https:\/\/doi.org\/10.1007\/s11864-014-0320-6","journal-title":"Curr Treat Options in Oncol"},{"issue":"3","key":"4736_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cancers12030546","volume":"12","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, Cabiddu M, Borgonovo K, Dognini G, Brighenti M, De Toma A, Rijavec E, Garassino MC, Grossi F, Tomasello G (2020) Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers 12(3):546. https:\/\/doi.org\/10.3390\/cancers12030546","journal-title":"Cancers"},{"issue":"5","key":"4736_CR38","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/brain\/aww046","volume":"139","author":"KL Pitter","year":"2016","unstructured":"Pitter KL, Tamagno I, Alikhanyan K et al (2016) Corticosteroids compromise survival in glioblastoma. Brain 139(5):1458\u20131471. https:\/\/doi.org\/10.1093\/brain\/aww046","journal-title":"Brain"},{"issue":"1","key":"4736_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaci.2020.04.044","volume":"147","author":"L Quatrini","year":"2021","unstructured":"Quatrini L, Vacca P, Tumino N et al (2021) Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. J Allergy Clin Immunol 147(1):349\u2013360. https:\/\/doi.org\/10.1016\/j.jaci.2020.04.044","journal-title":"J Allergy Clin Immunol"},{"key":"4736_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","volume":"145","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Genova C, De Giglio A et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145:479\u2013485. https:\/\/doi.org\/10.1007\/s00432-018-2805-3","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4736_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ncponc0062","volume":"2","author":"LC Richardson","year":"2005","unstructured":"Richardson LC, Pollack LA (2005) Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2(1):48\u201353. https:\/\/doi.org\/10.1038\/ncponc0062","journal-title":"Nat Clin Pract Oncol"},{"key":"4736_CR42","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cell.2017.09.016","volume":"171","author":"SP Rosshart","year":"2017","unstructured":"Rosshart SP, Vassallo BG, Angeletti D et al (2017) Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell 171:1015\u201328.e13","journal-title":"Cell"},{"issue":"12","key":"4736_CR43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11894-021-00829-y","volume":"23","author":"L Sattler","year":"2021","unstructured":"Sattler L, Hanauer SB, Malter L (2021) Immunomodulatory agents for treatment of patients with inflammatory bowel disease (review safety of anti-TNF, anti-integrin, anti IL-12\/23, JAK inhibition, sphingosine 1-phosphate receptor modulator, azathioprine\/6-MP and methotrexate). Curr Gastroenterol Rep 23(12):30. https:\/\/doi.org\/10.1007\/s11894-021-00829-y","journal-title":"Curr Gastroenterol Rep"},{"key":"4736_CR44","doi-asserted-by":"publisher","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Association of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 affirm study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). Ann Oncol 23:ix297. https:\/\/doi.org\/10.1016\/S0923-7534(20)33514-6","DOI":"10.1016\/S0923-7534(20)33514-6"},{"issue":"11","key":"4736_CR45","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","volume":"13","author":"SC Scott","year":"2018","unstructured":"Scott SC, Pennell NA (2018) Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol 13(11):1771\u20131775. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.004","journal-title":"J Thorac Oncol"},{"key":"4736_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ejca.2020.12.012","volume":"145","author":"M Skribek","year":"2021","unstructured":"Skribek M, Rounis K, Afshar S et al (2021) Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer 145:245\u2013254. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.012","journal-title":"Eur J Cancer"},{"issue":"6","key":"4736_CR47","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJMc2031717","volume":"384","author":"AS Thomas","year":"2021","unstructured":"Thomas AS, Ma W, Wang Y (2021a) Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med 384(6):581\u2013583. https:\/\/doi.org\/10.1056\/NEJMc2031717","journal-title":"N Engl J Med"},{"key":"4736_CR48","doi-asserted-by":"publisher","unstructured":"Thomas AS, Halsey T, Jiang ZD, DuPont H, Jenq R, Wang Y (2021b) S156 microbiome alteration via fecal microbiota transplantation (FMT) Is Effective for Immune Checkpoint Inhibitor (ICI) induced-colitis (IMC) refractory to immunosuppressive therapy. Off J Am Coll Gastroenterol ACG 116:S68. https:\/\/doi.org\/10.14309\/01.ajg.0000773096.64765.a8","DOI":"10.14309\/01.ajg.0000773096.64765.a8"},{"key":"4736_CR49","doi-asserted-by":"publisher","unstructured":"van Not OJ, Verheijden RJ, van den Eertwegh AJM et al (2022) Association of immune-related adverse event management with survival in patients with advanced melanoma (published online ahead of print, 2022 Oct 27). JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5041","DOI":"10.1001\/jamaoncol.2022.5041"},{"issue":"9","key":"4736_CR50","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","volume":"26","author":"RJ Verheijden","year":"2020","unstructured":"Verheijden RJ, May AM, Blank CU et al (2020) Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the dutch melanoma treatment registry. Clin Cancer Res 26(9):2268\u20132274. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3322","journal-title":"Clin Cancer Res"},{"issue":"6264","key":"4736_CR51","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079\u20131084. https:\/\/doi.org\/10.1126\/science.aad1329","journal-title":"Science"},{"issue":"8","key":"4736_CR52","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/ibd\/izy104","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E et al (2018b) Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 24(8):1695\u20131705. https:\/\/doi.org\/10.1093\/ibd\/izy104","journal-title":"Inflamm Bowel Dis"},{"key":"4736_CR53","doi-asserted-by":"publisher","unstructured":"Wang Y, Abu-Sbeih H, Mao E et al (2018a) Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 6:37. https:\/\/doi.org\/10.1186\/s40425-018-0346-6","DOI":"10.1186\/s40425-018-0346-6"},{"key":"4736_CR54","doi-asserted-by":"publisher","unstructured":"Wang Y, Ma W, Abu-Sbeih H, Jiang ZD, DuPont HL (2020) Fecal microbiota transplantation (FMT) for immune checkpoint inhibitor induced-colitis (IMC) refractory to immunosuppressive therapy. JCO 38(15_suppl):3067\u20133067. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.3067","DOI":"10.1200\/JCO.2020.38.15_suppl.3067"},{"key":"4736_CR55","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1053\/j.gastro.2017.08.022","volume":"153","author":"SH Wong","year":"2017","unstructured":"Wong SH, Zhao L, Zhang X et al (2017) Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 153:1621\u201333.e6","journal-title":"Gastroenterology"},{"issue":"5","key":"4736_CR56","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.dsx.2018.04.028","volume":"12","author":"NV Yunusova","year":"2018","unstructured":"Yunusova NV, Kondakova IV, Kolomiets LA, Afanas\u2019ev SG, Kishkina AY, Spirina LV (2018) The role of metabolic syndrome variant in the malignant tumors progression. Diabetes Metab Syndr 12(5):807\u2013812. https:\/\/doi.org\/10.1016\/j.dsx.2018.04.028","journal-title":"Diabetes Metab Syndr"},{"key":"4736_CR57","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.14309\/ajg.0000000000000848","volume":"115","author":"F Zou","year":"2020","unstructured":"Zou F, Shah AY, Glitza IC, Richards D, Thomas AS, Wang Y (2020) S0137 comparative study of vedolizumab and infliximab treatment in patients with immune-mediated diarrhea and colitis. Off J Am Coll Gastroenterol ACG 115:S68. https:\/\/doi.org\/10.14309\/ajg.0000000000000848","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"4736_CR58","doi-asserted-by":"publisher","unstructured":"Zou F, Faleck D, Thomas A et al (2021) Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 9(11):e003277. https:\/\/doi.org\/10.1136\/jitc-2021-003277","DOI":"10.1136\/jitc-2021-003277"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04736-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04736-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04736-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T13:47:35Z","timestamp":1690465655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04736-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4736"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04736-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,8]]},"assertion":[{"value":"26 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics approval for this study was granted by the institutional review board at The University of Texas MD Anderson Cancer Center (PA18-0472). Patient consent was waived for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}